Both in Pharmaceuticals
Rapport Therapeutics vs UroGen Pharma
Over the past year RAPP returned −2.7% and URGN returned +45.1%; their daily moves had a correlation of 0.17.
RAPP −2.7% URGN +45.1%Growth of $1, one year, split-adjusted
| Metric | RAPP | URGN |
|---|---|---|
| Price | $25.93 | $28.74 |
| Market cap | $1.46B | $1.40B |
| Today | +1.93% | −16.45% |
| 1 month | −16.8% | −30.6% |
| 6 months | −30.0% | +9.5% |
| Year to date | −14.5% | +22.7% |
| 1 year | −3.7% | +39.4% |
| Revenue growth (YoY) | — | +199.2% |
| Gross margin | — | 90.9% |
| Net margin | — | −19.8% |
| P/E (TTM) | — | — |
| Price / sales | 73.0× | 7.4× |
| Net cash | $436.1M | -$85.1M |
| Dividend yield | — | — |
| Volatility (60d) | 79.1% | 54.9% |
| Short % of float | 10.9% | 12.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).